Mereo BioPharma Group plc
MREO
$2.74
$0.2811.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.13% | 79.43% | 8.67% | 194.79% | -8.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.92% | 82.60% | 1.80% | 35.42% | -13.64% |
| Operating Income | -16.92% | -108.50% | -1.80% | -6,450.00% | 13.64% |
| Income Before Tax | -43.97% | 26.92% | -129.69% | -599.89% | 25.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.97% | 22.65% | -129.69% | -599.89% | 25.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.97% | 22.65% | -129.69% | -599.89% | 25.88% |
| EBIT | -16.92% | -108.50% | -1.80% | -6,450.00% | 13.64% |
| EBITDA | -17.24% | -111.10% | -1.87% | -28,537.21% | 14.17% |
| EPS Basic | -28.64% | 30.11% | -104.19% | -519.42% | 33.99% |
| Normalized Basic EPS | -28.57% | 34.11% | -104.36% | -518.39% | 34.05% |
| EPS Diluted | -28.64% | 30.11% | -104.19% | -519.42% | 33.99% |
| Normalized Diluted EPS | -28.57% | 34.11% | -104.36% | -518.39% | 34.05% |
| Average Basic Shares Outstanding | 12.00% | 10.75% | 12.43% | 13.26% | 12.24% |
| Average Diluted Shares Outstanding | 12.00% | 10.75% | 12.43% | 13.26% | 12.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |